US Bancorp DE Sells 1,988 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

US Bancorp DE lowered its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 16.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 9,983 shares of the biotechnology company’s stock after selling 1,988 shares during the quarter. US Bancorp DE’s holdings in Blueprint Medicines were worth $871,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Empirical Asset Management LLC bought a new position in Blueprint Medicines during the fourth quarter valued at $2,348,000. Stephens Inc. AR bought a new position in Blueprint Medicines during the 4th quarter valued at about $321,000. Massachusetts Financial Services Co. MA raised its position in Blueprint Medicines by 48.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock worth $23,332,000 after purchasing an additional 82,693 shares during the period. Entropy Technologies LP bought a new stake in Blueprint Medicines in the third quarter worth about $999,000. Finally, KBC Group NV boosted its position in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Wedbush restated an “outperform” rating and issued a $128.00 price target on shares of Blueprint Medicines in a report on Friday, February 28th. Piper Sandler upped their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. StockNews.com cut Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $125.21.

Blueprint Medicines Stock Down 1.6 %

Blueprint Medicines stock opened at $87.12 on Monday. Blueprint Medicines Co. has a 1-year low of $80.68 and a 1-year high of $121.90. The business has a fifty day moving average price of $99.38 and a 200-day moving average price of $94.21. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of -80.67 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares of the company’s stock, valued at approximately $1,692,167.40. The trade was a 14.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kate Haviland sold 1,446 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at $16,467,430.72. This represents a 0.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,427 shares of company stock valued at $4,837,801. Insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.